Slight Improvement In 1994 For Sorin
Net profits in 1994 at Sorin Biomedica amounted to 12.8 billion lire ($7.6 million), up 12.3%. Operating profits were 99.1 billion lire, compared with 87 billion in 1993. Consolidated group sales were ahead 5% to 837.1 billion lire. 64% of this total was generated outside of Italy.
The parent company posted operating profit of 12.9 billion lire and sales of 151.4 billion lire. The results are not comparable with the previous year because of the spin-off of the cardiovascular activities at the end of 1993.
Sorin invested 92.5 billion lire or 11% of sales, including R&D, in 1994. This is 2.9% below the amount spent in 1993.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze